Contact us for information regarding our sample policy
standard
Western Europe Australia North America South America Eastern Europe Middle East Africa Central America Asia
All India
depend
Product Description
Trelagliptin (Zafatek(®)) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly.